Relationship between serum interleukin-17 and matrix metalloproteinase-13 and progression-free survival and overall survival in patients with multiple myeloma in partial remission

Feng Suli; Zhao Yanmei

doi:10.3760/j.issn.1673-4777.2025.09.015

Abstract：Objective To investigate the relationship between serum levels of interleukin-17(IL-17)and matrix metalloproteinase-13(MMP-13)and progression-free survival(PFS)and overall survival in patients with multiple myeloma in partial remission.Methods A total of 105 patients with multiple myeloma who achieved partial remission after clinical treatment in Zhejiang Provincial People's Hospital from June 2019 to May 2021 were selected as the research objects.The clinical data of the patients were collected,and the serum levels of IL-17 and MMP-13 were detected.All patients were followed up regularly after discharge to calculate survival,PFS and overall survival.Receiver operating characteristic(ROC)curve was used to analyze the predictive value of serum IL-17 and MMP-13 levels for the prognosis of patients with partial remission.According to the optimal cut-off value of ROC,the patients were divided into high IL-17 group and low IL-17 group,high MMP-13 group and low MMP-13 group.PFS and overall survival were compared between groups.Cox regression analysis model was used to analyze the influencing factors of PFS and overall survival in patients with multiple myeloma.Results At the end of the follow-up,77 of 105 patients survived and 28 died,with an overall survival rate of 73.3％(77/105)and a mortality rate of 26.7％(28/105).ROC curve analysis showed that the best cut-off value of IL-17 to predict the prognosis of death in patients with multiple myeloma at partial remission was 30.85 ng/L,the area under the curve(AUC)=0.780,and the best cut-off value of MMP-13 to predict the prognosis of death in patients with multiple myeloma was 10.68 ng/L,AUC=0.738.The PFS and overall survival of the high IL-17 group were shorter than those of the low IL-17 group[(19±4)months vs(29±5)months,(36±6)months vs(50±6)months](t=12.000,11.545,both P＜0.001).The PFS and overall survival of the high MMP-13 group were shorter than those of the low MMP-13 group[(21±4)months vs(27±5)months,(38±6)months vs(47±7)months](t=7.719,7.128,both P＜0.001).Multivariate Cox regression analysis showed that lactate dehydrogenase,β2-microglobulin,IL-17,MMP-13,age,1q amplification,and 17p-were the influencing factors of PFS in patients with multiple myeloma(all P＜0.05).β2-microglobulin,IL-17,MMP-13,age,1q amplification,and 17p-were the influencing factors of overall survival(all P＜0.05).Conclusion The serum levels of IL-17 and MMP-13 in patients with multiple myeloma during partial remission are related to PFS and overall survival,which can be used as an intermediate stage indicator to evaluate the prognosis of patients.